VTP 300
Alternative Names: ChAdOx1-HBV; Chimpanzee adenovirus-vectored hepatitis B virus vaccine - Barinthus Biotherapeutics; VTP-300Latest Information Update: 19 May 2025
At a glance
- Originator University of Oxford
- Developer Arbutus Biopharma; Barinthus Biotherapeutics
- Class Hepatitis B vaccines; Synthetic vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase II Hepatitis B
Most Recent Events
- 07 May 2025 Efficacy data from the phase IIa IM-PROVE II trial in Chronic hepatitis B infection released by Barinthus Biotherapeutics
- 07 May 2025 Efficacy data from the phase IIb HBV003 trial in Chronic hepatitis B infection released by Barinthus Biotherapeutics
- 14 Jan 2025 VTP 300 is available for licensing as of 10 Jan 2025. https://www.barinthusbio.com/